ESR1 and breast carcinoma: The identification of the nuclear estrogen receptor (ER) and the differentiation between ER-positive and ER-negative breast carcinomas in the 1970s by the American scientist Elwood Jensen marked a milestone and the beginning of a tumor biological approach in oncology, from which the still-existing anti-estrogen therapy originated.